Statistical process control of manufacturing tablets for antiretroviral therapy

Detalhes bibliográficos
Autor(a) principal: Rocha, Nataly Paredes da
Data de Publicação: 2023
Outros Autores: da Silva, Osvaldo Cirilo, Barbosa, Eduardo José, Soares, Gidel, Oliveira, Roberto, Monteiro, Lis Marie, Bou-Chacra, Nádia Araci
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/213090
Resumo: In this study, the manufacturing process of lamivudine (3TC) and zidovudine (AZT) tablets (150+300 mg respectively) was evaluated using statistical process control (SPC) tools. These medicines are manufactured by the Fundação para o Remédio Popular “Chopin Tavares de Lima” (FURP) laboratory, and are distributed free of charge to patients infected with HIV by the Ministry of Health DST/AIDS national program. Data of 529 batches manufactured from 2012 to 2015 were collected. The critical quality attributes of weight variation, uniformity of dosage units, and dissolution were evaluated. Process stability was assessed using control charts, and the capability indices Cp, Cpk, Pp, and Ppk (process capability; process capability adjusted for non-centered distribution; potential or global capability of the process; and potential process capability adjusted for non-centered distribution, respectively) were evaluated. 3TC dissolution data from 2013 revealed a non-centered process and lack of consistency compared to the other years, showing Cpk and Ppk lower than 1.0 and the chance of failure of 2,483 in 1,000,000 tablets. Dissolution data from 2015 showed process improvement, revealed by Cpk and Ppk equal to 2.19 and 1.99, respectively. Overall, the control charts and capability indices showed the variability of the process and special causes. Additionally, it was possible to point out the opportunities for process changes, which are fundamental for understanding and supporting a continuous improvement environment.
id USP-31_efe279b90e4f0c8a9998b175bf79b2fb
oai_identifier_str oai:revistas.usp.br:article/213090
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Statistical process control of manufacturing tablets for antiretroviral therapyCapability indicesControl chartsHIV treatmentManufacturing processQuality toolsIn this study, the manufacturing process of lamivudine (3TC) and zidovudine (AZT) tablets (150+300 mg respectively) was evaluated using statistical process control (SPC) tools. These medicines are manufactured by the Fundação para o Remédio Popular “Chopin Tavares de Lima” (FURP) laboratory, and are distributed free of charge to patients infected with HIV by the Ministry of Health DST/AIDS national program. Data of 529 batches manufactured from 2012 to 2015 were collected. The critical quality attributes of weight variation, uniformity of dosage units, and dissolution were evaluated. Process stability was assessed using control charts, and the capability indices Cp, Cpk, Pp, and Ppk (process capability; process capability adjusted for non-centered distribution; potential or global capability of the process; and potential process capability adjusted for non-centered distribution, respectively) were evaluated. 3TC dissolution data from 2013 revealed a non-centered process and lack of consistency compared to the other years, showing Cpk and Ppk lower than 1.0 and the chance of failure of 2,483 in 1,000,000 tablets. Dissolution data from 2015 showed process improvement, revealed by Cpk and Ppk equal to 2.19 and 1.99, respectively. Overall, the control charts and capability indices showed the variability of the process and special causes. Additionally, it was possible to point out the opportunities for process changes, which are fundamental for understanding and supporting a continuous improvement environment.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2023-06-13info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/21309010.1590/s2175-97902023e22099 Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023)Brazilian Journal of Pharmaceutical Sciences; v. 59 (2023)Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023)2175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/213090/195064Copyright (c) 2023 Brazilian Journal of Pharmaceutical Scienceshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessRocha, Nataly Paredes dada Silva, Osvaldo Cirilo Barbosa, Eduardo JoséSoares, Gidel Oliveira, RobertoMonteiro, Lis MarieBou-Chacra, Nádia Araci 2023-06-13T14:15:36Zoai:revistas.usp.br:article/213090Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2023-06-13T14:15:36Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Statistical process control of manufacturing tablets for antiretroviral therapy
title Statistical process control of manufacturing tablets for antiretroviral therapy
spellingShingle Statistical process control of manufacturing tablets for antiretroviral therapy
Rocha, Nataly Paredes da
Capability indices
Control charts
HIV treatment
Manufacturing process
Quality tools
title_short Statistical process control of manufacturing tablets for antiretroviral therapy
title_full Statistical process control of manufacturing tablets for antiretroviral therapy
title_fullStr Statistical process control of manufacturing tablets for antiretroviral therapy
title_full_unstemmed Statistical process control of manufacturing tablets for antiretroviral therapy
title_sort Statistical process control of manufacturing tablets for antiretroviral therapy
author Rocha, Nataly Paredes da
author_facet Rocha, Nataly Paredes da
da Silva, Osvaldo Cirilo
Barbosa, Eduardo José
Soares, Gidel
Oliveira, Roberto
Monteiro, Lis Marie
Bou-Chacra, Nádia Araci
author_role author
author2 da Silva, Osvaldo Cirilo
Barbosa, Eduardo José
Soares, Gidel
Oliveira, Roberto
Monteiro, Lis Marie
Bou-Chacra, Nádia Araci
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Rocha, Nataly Paredes da
da Silva, Osvaldo Cirilo
Barbosa, Eduardo José
Soares, Gidel
Oliveira, Roberto
Monteiro, Lis Marie
Bou-Chacra, Nádia Araci
dc.subject.por.fl_str_mv Capability indices
Control charts
HIV treatment
Manufacturing process
Quality tools
topic Capability indices
Control charts
HIV treatment
Manufacturing process
Quality tools
description In this study, the manufacturing process of lamivudine (3TC) and zidovudine (AZT) tablets (150+300 mg respectively) was evaluated using statistical process control (SPC) tools. These medicines are manufactured by the Fundação para o Remédio Popular “Chopin Tavares de Lima” (FURP) laboratory, and are distributed free of charge to patients infected with HIV by the Ministry of Health DST/AIDS national program. Data of 529 batches manufactured from 2012 to 2015 were collected. The critical quality attributes of weight variation, uniformity of dosage units, and dissolution were evaluated. Process stability was assessed using control charts, and the capability indices Cp, Cpk, Pp, and Ppk (process capability; process capability adjusted for non-centered distribution; potential or global capability of the process; and potential process capability adjusted for non-centered distribution, respectively) were evaluated. 3TC dissolution data from 2013 revealed a non-centered process and lack of consistency compared to the other years, showing Cpk and Ppk lower than 1.0 and the chance of failure of 2,483 in 1,000,000 tablets. Dissolution data from 2015 showed process improvement, revealed by Cpk and Ppk equal to 2.19 and 1.99, respectively. Overall, the control charts and capability indices showed the variability of the process and special causes. Additionally, it was possible to point out the opportunities for process changes, which are fundamental for understanding and supporting a continuous improvement environment.
publishDate 2023
dc.date.none.fl_str_mv 2023-06-13
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/213090
10.1590/s2175-97902023e22099
url https://www.revistas.usp.br/bjps/article/view/213090
identifier_str_mv 10.1590/s2175-97902023e22099
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/213090/195064
dc.rights.driver.fl_str_mv Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Brazilian Journal of Pharmaceutical Sciences
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023)
Brazilian Journal of Pharmaceutical Sciences; v. 59 (2023)
Brazilian Journal of Pharmaceutical Sciences; Vol. 59 (2023)
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222918131580928